Iqbal J. Hussain Sells 77,705 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 77,705 shares of the business's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $16.39, for a total value of $1,273,584.95. Following the transaction, the general counsel now directly owns 125,785 shares in the company, valued at $2,061,616.15. This trade represents a 38.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Up 5.1 %

Shares of CNTA stock traded up $0.85 during trading on Tuesday, reaching $17.60. The company's stock had a trading volume of 816,790 shares, compared to its average volume of 431,601. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.50 and a beta of 1.52. The stock's 50-day moving average price is $16.53 and its 200 day moving average price is $13.40. Centessa Pharmaceuticals plc has a 1-year low of $6.65 and a 1-year high of $18.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently modified their holdings of CNTA. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after buying an additional 826 shares during the last quarter. Atria Investments Inc lifted its position in Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company's stock valued at $274,000 after purchasing an additional 1,116 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Centessa Pharmaceuticals by 103.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock valued at $48,000 after buying an additional 1,509 shares during the period. Quarry LP boosted its position in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company's stock worth $87,000 after purchasing an additional 3,108 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 99.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company's stock worth $217,000 after purchasing an additional 6,785 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CNTA. Jefferies Financial Group boosted their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a "buy" rating and a $33.00 price target on the stock. BMO Capital Markets increased their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research report on Monday, September 16th. Finally, Guggenheim lifted their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of "Buy" and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.